Taken together, our findings indicate that elevated PUM2 expression and subsequent down regulation of BTG1 is one of the molecular characteristics of glioblastoma, suggesting that PUM2 and its downstream cellular pathways can be a potential pharmacotherapeutic target. Here, BTG1 is linked to glioblastoma.